Hematopoietic cell transplantation: five decades of progress.

[1]  S. Heimfeld,et al.  HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. , 2003, Blood.

[2]  H. Deeg,et al.  Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. , 2003, Blood.

[3]  R. Storb,et al.  Postgrafting immunosuppression with sirolimus and cyclosporine facilitates stable mixed hematopoietic chimerism in dogs given sublethal total body irradiation before marrow transplantation from DLA-identical littermates. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  M. Maris,et al.  Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. , 2003, Blood.

[5]  M. Brechbiel,et al.  Selective T-cell ablation with bismuth-213–labeled anti-TCRαβ as nonmyeloablative conditioning for allogeneic canine marrow transplantation , 2003 .

[6]  J. Goldman,et al.  Human cytotoxic T lymphocytes specific for Wilms’ tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients , 2003, Transplantation.

[7]  M. Maris,et al.  Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  Els Goulmy,et al.  Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[9]  R. Storb,et al.  Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissio , 2003, Blood.

[10]  P. Pisa,et al.  Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma , 2003, Bone Marrow Transplantation.

[11]  M. Maris,et al.  Non‐myeloablative allografting from human leucocyte antigen‐identical sibling donors for treatment of acute myeloid leukaemia in first complete remission , 2003, British journal of haematology.

[12]  F. Baron,et al.  Non-myeloablative stem cell transplantation with low-dose total body irradiation and fludarabine for metastatic renal cell carcinoma. , 2003, Haematologica.

[13]  R. Storb.  Allogeneic hematopoietic stem cell transplantation--yesterday, today, and tomorrow. , 2003, Experimental hematology.

[14]  J. Bourhis,et al.  Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. , 2002, Blood.

[15]  M. Maris,et al.  Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  J Wagner,et al.  Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. , 2002, Blood.

[17]  T. Panzarella,et al.  A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. , 2002, Blood.

[18]  H. Deeg,et al.  Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. , 2002, Blood.

[19]  R. Storb,et al.  Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. , 2002, Blood.

[20]  Y. Beguin,et al.  Preemptive cellular immunotherapy after T-cell-depleted allogeneic hematopoietic stem cell transplantation. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[21]  J. Bourhis,et al.  Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression. , 2002, Blood.

[22]  M. Maris,et al.  Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. , 2002, Blood.

[23]  Todd,et al.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.

[24]  H. Deeg,et al.  Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. , 2001, Blood.

[25]  R. Storb,et al.  Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. , 2001, Blood.

[26]  R. Storb,et al.  G-CSF-mobilized peripheral blood mononuclear cells added to marrow facilitates engraftment in nonmyeloablated canine recipients: CD3 cells are required. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[27]  R. Storb,et al.  Effects of extending the duration of postgrafting immunosuppression and substituting granulocyte-colony-stimulating factor-mobilized peripheral blood mononuclear cells for marrow in allogeneic engraftment in a nonmyeloablative canine transplantation model. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[28]  J. Radich,et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.

[29]  R Storb,et al.  Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. , 2001, The New England journal of medicine.

[30]  H. Deeg,et al.  Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[31]  J. Fay,et al.  Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. , 2000, Blood.

[32]  W. Linehan,et al.  Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. , 2000, The New England journal of medicine.

[33]  Mark M. Davis,et al.  Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia , 2000, Nature Medicine.

[34]  R. Collins,et al.  Donor leukocyte infusions in acute lymphocytic leukemia , 2000, Bone Marrow Transplantation.

[35]  J. Ritz,et al.  Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[36]  Jane L. Liesveld,et al.  Handbook of Bone Marrow Transplantation , 2000 .

[37]  S. Saidman,et al.  Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[38]  Y. Beguin,et al.  Adoptive immunotherapy with donor lymphocyte infusionsafter allogeneic HPC transplantation , 2000, Transfusion.

[39]  R. Storb,et al.  Mini-allografts: ongoing trials in humans , 2000, Bone Marrow Transplantation.

[40]  R. Storb,et al.  Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia. , 1999, Blood.

[41]  N. Young,et al.  Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. , 1999, Blood.

[42]  H. Deeg,et al.  Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. , 1999, Blood.

[43]  H. Deeg,et al.  Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. , 1999, Blood.

[44]  S. Saidman,et al.  Mixed lymphohaemopoietic chimerism and graft-ver suslymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation , 1999, The Lancet.

[45]  J. Adamson,et al.  Outcomes Among 562 Recipients of Placental-Blood Transplants From Unrelated Donors , 1999 .

[46]  J. Adamson,et al.  Outcomes among 562 recipients of placental-blood transplants from unrelated donors. , 1998, The New England journal of medicine.

[47]  N. Ueno,et al.  Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  N. Schmitz,et al.  Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation , 1998, Bone Marrow Transplantation.

[49]  C Anasetti,et al.  Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. , 1998, The New England journal of medicine.

[50]  A. Nagler,et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.

[51]  C. Chastang,et al.  Outcome of cord-blood transplantation from related and unrelated donors , 1997 .

[52]  E. Estey,et al.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. , 1997, Blood.

[53]  E. Goulmy.  Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy , 1997, Immunological reviews.

[54]  H. Deeg,et al.  Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. , 1997, Blood.

[55]  L. Brent.  A history of transplantation immunology , 1996 .

[56]  J. Scott,et al.  Bone marrow transplantation for sickle cell disease. , 1996, The New England journal of medicine.

[57]  J. Kurtzberg,et al.  Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. , 1996, The New England journal of medicine.

[58]  A. Nagler,et al.  Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. , 1995, Experimental hematology.

[59]  H. Deeg,et al.  DLA-identical bone marrow grafts after low-dose total body irradiation: effects of high-dose corticosteroids and cyclosporine on engraftment. , 1995, Blood.

[60]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.

[61]  R. Cobley.  A history of transplantation. , 1995, International history of nursing journal : IHNJ.

[62]  H. Deeg,et al.  Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. , 1994, Blood.

[63]  H. Deeg,et al.  Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. , 1994, Blood.

[64]  J. Sosman,et al.  Allogeneic T-cell clones able to selectively destroy Philadelphia chromosome-bearing (Ph1+) human leukemia lines can also recognize Ph1- cells from the same patient. , 1994, Blood.

[65]  A. Rimm,et al.  Identical-Twin Bone Marrow Transplants for Leukemia , 1994, Annals of Internal Medicine.

[66]  H. Deeg,et al.  FK‐506 AND METHOTREXATE PREVENT GRAFT‐VERSUS-HOST DISEASE IN DOGS GIVEN 9.2 Gy TOTAL BODY IRRADIATION AND MARROW GRAFTS FROM UNRELATED DOG LEUKOCYTE ANTIGEN‐NONIDENTICAL DONORS , 1993, Transplantation.

[67]  M. Andreani,et al.  Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. , 1993, The New England journal of medicine.

[68]  G. Snell,et al.  The Nobel Lectures in Immunology. Lecture for the Nobel Prize for Physiology or Medicine, 1980: Studies in histocompatibility. , 1992, Scandinavian journal of immunology.

[69]  A. Rimm,et al.  T-cell depletion of HLA-identical transplants in leukemia. , 1991, Blood.

[70]  W. Wilmanns,et al.  Donor Leukocyte Transfusions for Treatment of Recurrent Chronic Myelogenous Leukemia in Marrow Transplant Patients , 1990 .

[71]  G. Lucarelli,et al.  Bone marrow transplantation in patients with thalassemia. , 1990, The New England journal of medicine.

[72]  R Storb,et al.  Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. , 1989, Blood.

[73]  R. Storb,et al.  What radiation dose for DLA-identical canine marrow grafts? [published erratum appears in Blood 1989 Feb;73(2):624] , 1988 .

[74]  R. Hoffmann,et al.  Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. , 1988 .

[75]  D. Brahams.  Human immunodeficiency virus and the law. , 1987, Lancet.

[76]  D. Blaise,et al.  IMPACT OF T-CELL DEPLETION ON OUTCOME OF ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR STANDARD-RISK LEUKAEMIAS , 1987, The Lancet.

[77]  H. Deeg,et al.  Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. , 1986, Blood.

[78]  H. Deeg,et al.  Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.

[79]  H. Deeg,et al.  Marrow transplantation for the treatment of chronic myelogenous leukemia. , 1986, Annals of internal medicine.

[80]  R. Marcus,et al.  Bone marrow transplantation for patients with chronic myeloid leukemia. , 1986, The New England journal of medicine.

[81]  R. Storb,et al.  Graft‐versus‐Host Disease in Dog and Man: The Seattle Experience , 1985, Immunological reviews.

[82]  H. Deeg,et al.  Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts , 1985 .

[83]  A. Look,et al.  Bone-marrow transplantation in a patient with sickle-cell anemia. , 1984, The New England journal of medicine.

[84]  R. Brookmeyer,et al.  Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. , 1983, The New England journal of medicine.

[85]  K. Sullivan,et al.  MARROW TRANSPLANTATION FOR THALASSAEMIA , 1982, The Lancet.

[86]  R. Storb,et al.  Marrow transplantation for acute nonlymphoblastic leukemic in first remission using fractionated or single-dose irradiation. , 1982, International journal of radiation oncology, biology, physics.

[87]  K. Sullivan,et al.  Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. , 1981, The New England journal of medicine.

[88]  P. Neiman,et al.  Marrow transplantation for acute nonlymphoblastic leukemia in first remission. , 1979, The New England journal of medicine.

[89]  R. Storb,et al.  Marrow transplantation for patients with acute lymphoblastic leukemia in remission. , 1979, Blood.

[90]  R. Storb,et al.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.

[91]  P. Neiman,et al.  One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. , 1977, Blood.

[92]  R Storb,et al.  Bone-marrow transplantation (first of two parts). , 1975, The New England journal of medicine.

[93]  S. Agarwal,et al.  Letter: Alpha-fetoprotein in Indian childhood cirrhosis. , 1974, Lancet.

[94]  B. Speck,et al.  Allogeneic bone marrow transplantation in a patient with aplastic anemia using a phenotypically HL-A-identifcal unrelated donor. , 1973, Transplantation.

[95]  P. Neiman,et al.  Leukaemic transformation of engrafted human marrow cells in vivo. , 1971, Lancet.

[96]  M. Bortin.  A COMPENDIUM OF REPORTED HUMAN BONE MARROW TRANSPLANTS , 1970, Transplantation.

[97]  R. Storb,et al.  METHOTREXATE REGIMENS FOR CONTROL OF GRAFT-VERSUS-HOST DISEASE IN DOGS WITH ALLOGENEIC MARROW GRAFTS , 1970, Transplantation.

[98]  R. Gatti,et al.  Immunological reconstitution of sex-linked lymphopenic immunological deficiency. , 1968, Lancet.

[99]  R. Storb,et al.  CYTOTOXIC TYPING ANTISERA FOR MARROW GRAFTING IN LITTERMATE DOGS , 1968, Transplantation.

[100]  M. Woodruff.  Transplantation of tissues and organs , 1967 .

[101]  G. Mathé,et al.  Adoptive immunotherapy of acute leukemia: experimental and clinical results. , 1965, Cancer research.

[102]  J. Andrews.  DOSE-TIME RELATIONSHIPS IN CANCER RADIOTHERAPY. A CLINICAL RADIOBIOLOGY STUDY OF EXTREMES OF DOSE AND TIME. , 1965, The American journal of roentgenology, radium therapy, and nuclear medicine.

[103]  A. Levy,et al.  Prevention of Delayed Foreign Marrow Reaction in Lethally Irradiated Mice by Early Administration of Methotrexate , 1962, Nature.

[104]  D. Parkin,et al.  Prolonged Survival of a Bone-marrow Graft Resulting in a Blood-group Chimera* , 1960, British medical journal.

[105]  R. Billingham,et al.  Quantitative studies on tissue transplantation immunity IV. Induction of tolerance in newborn mice and studies on the phenomenon of runt disease , 1959, Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences.

[106]  P. Russell,et al.  Treatment of terminal leukemic relapse by total-body irradiation and intravenous infusion of stored autologous bone marrow obtained during remission. , 1959, The New England journal of medicine.

[107]  F. Burnet.  The clonal selection theory of acquired immunity , 1959 .

[108]  D. Uphoff.  Alteration of Homograft Reaction by A-methopterin in Lethally Irradiated Mice Treated with Homologous Marrow , 1958, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[109]  E. Thomas,et al.  Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. , 1957, The New England journal of medicine.

[110]  D. Uphoff.  Genetic factors influencing irradiation protection by bone marrow. I. The F1 hybrid effect. , 1957, Journal of the National Cancer Institute.

[111]  J. Loutit,et al.  Treatment of Murine Leukaemia with X‐Rays and Homologous Bone Marrow: II , 1957, British journal of haematology.

[112]  J. Loutit,et al.  Treatment of Murine Leukaemia with X Rays and Homologous Bone Marrow , 1956, British medical journal.

[113]  J. Trentin.  Mortality and Skin Transplantability in X-Irradiated Mice Receiving Isologous, Homologous or Heterologous Bone Marrow.∗ † , 1956, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[114]  T. Makinodan.  Circulating Rat Cells in Lethally Irradiated Mice Protected with Rat Bone Marrow.∗ , 1956, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[115]  C. E. Ford,et al.  Cytological Identification of Radiation-Chimæras , 1956, Nature.

[116]  P. Nowell,et al.  Growth and continued function of rat marrow cells in x-radiated mice. , 1956, Cancer research.

[117]  D. V. van Bekkum,et al.  Evidence for the cellular hypothesis in radiation protection by bone marrow cells. , 1956, Acta physiologica et pharmacologica Neerlandica.

[118]  D. Lindsley,et al.  Implantation of Functional Erythropoietic Elements Following Total-Body Irradiation.∗ , 1955, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[119]  R. Prehn,et al.  Successful skin homografts after the administration of high dosage X radiation and homologous bone marrow. , 1955, Journal of the National Cancer Institute.

[120]  P. Medawar,et al.  ‘Actively Acquired Tolerance’ of Foreign Cells , 1953, Nature.

[121]  E. Shelton,et al.  Modification of irradiation injury in mice and guinea pigs by bone marrow injections. , 1951, Journal of the National Cancer Institute.

[122]  L. Jacobson,et al.  Recovery from radiation injury. , 1951, Science.

[123]  L. Jacobson,et al.  Further studies on recovery from radiation injury. , 1951, The Journal of laboratory and clinical medicine.

[124]  R. Owen.  IMMUNOGENETIC CONSEQUENCES OF VASCULAR ANASTOMOSES BETWEEN BOVINE TWINS. , 1945, Science.